Intramuscular Versus Intravenous Prophylactic Oxytocin for Hemorrhage After Vaginal Delivery

Intramuscular Versus Intravenous Prophylactic Oxytocin for the Third Stage of Labour Following Vaginal Delivery: A Randomised Controlled Trial

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02080104

Acronym

oxytocin

Enrollment

Registered

2014-03-06

Start date

2014-02-28

Completion date

2015-02-28

Last updated

2014-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum Hemorrhage

Keywords

postpartum hemorrhage, oxytocin, vaginal delivery, prophylactic

Brief summary

Intramuscular versus intravenous prophylactic oxytocin for the third stage of labour following vaginal delivery: A randomised controlled trial

Detailed description

Prevention of postpartum haemorrhage is essential in the pursuit of improved health care for women. In this study investigators aimed to compare intramuscular oxytocin with intravenous oxytocin for the routine prevention of postpartum haemorrhage in women who deliver vaginally.In some countries, intravenous access can not be provided easily . Intramuscular application is faster , easier and tougher enforcement requires less skill and equipment . For this reason, less educated , which can be applied by those offering health services .

Interventions

DRUGintarvenous and intramusculer 10 IU oxytocin

intarvenous and intramusculer 10 IU oxytocin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Inclusion criteria

1. Research volunteers, the undersigned, pregnant women 2. Only with vaginal delivery (episiotomy and perineal tears can) 3. \> 34 weeks or more will be 4. Cephalic presentation will be 5. At low risk of postpartum hemorrhage

Exclusion criteria

1. \<18 years 2. Multiple pregnancies 3. The presence of uterine myoma 4. Having postpartum hemorrhage in previous pregnancies 5. Placenta previa, polyhydramnios 6. More than four parity 7. Fetal macrosomia 8. Hb \<9mg/dl 9. preeclampsia 10. Uterine anomalies 11. Receiving anticoagulant therapy, suspected coagulopathy 12. \> 42 weeks of pregnancy 13. Oxytocin allergy -

Design outcomes

Primary

Measure	Time frame	Description
early postpartum hemorrhage	postpartum 24 hours	Blood loss during the birth and postpartum hemorrhage asset (within 24 hours\> 500 cc blood loss)

Secondary

Measure	Time frame	Description
Blood transfusion requirement	postpartum 24 hours	* Blood transfusion requirement * duration of phase 3 (\> 30 min) * necessity of additional treatments for postpartum hemorrhage * the necessity of manual removal of placenta * side effects of the

Countries

Turkey (Türkiye)

Contacts

Primary Contactnurten kayacan aydemir

nurten.aydemir@beah.gov.tr2124147171

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026